Tuesday, 5 June, 2007 - 22:00
Foundation set for Stone Ridge
Venture capital managers Rob Newman and Matt Callahan have completed a major restructuring and expansion of their Perth business, which has about $60 million under management.
Matt Callahan is a Perth-raised life sciences and health tech executive currently based in Pennsylvania. He had spent more than 25 years in legal, IP and investment management roles.
Mr Callahan has been the founding chief executive or executive director of several pharmaceutical and health tech companies including ASX-listed Botanix Pharmaceutical, iCeutica, Churchill Pharma, Dimerix Biosciences, Emerald Clinics, Orthocell, and Respirion Pharmaceutical. He has led the development of four products that have received FDA approval.
Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, technology and other sectors; and was general manager of Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.
Mr Callahan holds a Bachelor of Laws (Honours) from the University of WA, an MBA, and is a winner of the Business News 40under40 award in 2002.
Name | Current company |
---|
![]() |
NEWS: Tagged in Board Moves August 21, 2023 | 21 Aug 2023 |
![]() |
NEWS: Tagged in Promise of new era in venture capital | 29 Mar 2023 |
![]() |
NEW ROLE: Co-Founder, Rumin8 | 23 Jan 2023 |
Venture capital managers Rob Newman and Matt Callahan have completed a major restructuring and expansion of their Perth business, which has about $60 million under management.
Perth’s tight-knit angel investment community is growing more comfortable with soft tech plays, but there are calls for more investment in the ‘trickier’ tech.
Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.
Biotech Botanix Pharmaceuticals has raised $7.4 million in a placement of new shares to help it fund the further development of its dermatology products that contain a synthetic form of the cannabis compound, cannabidiol.
Shares in medical dermatology company Botanix Pharmaceuticals, led by Perth-based chairman Graham Griffiths and executive director Matt Callahan, have jumped more than 20 per cent today after the company announced successful results from an acne patient study.
Medical dermatology company Botanix Pharmaceuticals has raised $15 million through a strongly supported share placement, with the proceeds set to be spent on developing its lead product for acne.
Two local biotech companies have announced capital raisings today, with Botanix Pharmaceuticals tapping investors for $8 million, while Roto-Gro International has boosted its coffers with a $4.5 million raising.
A carefully managed five-year incubation process for new Perth company Respirion Pharmaceuticals has resulted in one of the largest funding deals for Western Australia’s biotech sector.
Botanix Pharmaceuticals has appointed Vince Ippolito as its president in the US, and subject to shareholder approval, he will also assume the role of executive chairman for the company.
Our daily board moves wrap includes Matt Callahan, Simon Paull, Alan Armstrong, David Rich, and Patrick Glovac.
Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.
Matt Callahan has re-joined the board of Botanix Pharmaceuticals as an executive director following the decision by Robert Towner to step down as non-executive director.
The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.
A Perth-based pharmaceutical founded by 40under40 winner Matt Callahan has acquired its first product in a bid to manoeuvre from research and development status to revenue-generating.
Climate technology company Rumin8 has raised $US12 million in a funding round led by the Bill Gates-founded Breakthrough Energy Ventures and supported by Andrew and Nicola Forrest.
Three new local funds proposing to focus on early-stage investment are raising expectations.
Our board moves wrap includes Jeremy Robinson, Matt Freedman, Michelle Roth, Bruce McFadzean, Mohit Kaushal, Matt Callahan, Simon Linge, and Bruce Munro.
Access to our data for Matt Callahan is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Matt Callahan is linked to 11 organisations which are included in 2 lists - Public Companies - Industrial WA and Technology Companies.
To see the data you will need to Subscribe.